Log in to your Inderes Free account to see all free content on this page.
Nanoform Finland
0.99 EUR
+6.24 %
3,631 following
NANOFH
First North Finland
Medical Equipment & Services
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+6.24 %
-12.26 %
+19.18 %
+12.15 %
-28.82 %
-29.93 %
-70.29 %
-77.81 %
-80.44 %
Nanoform Finland operates in the medical technology sector. The company specializes in research and development of nanoparticle technology used to create nanoparticles in pharmaceuticals. The technology is used as a complement in the production process and is used for the treatment of diseases such as ALS and Alzheimer's. Customers consist of players in the global pharmaceutical industry, with the largest operations in the Nordic market. Nanoform Finland is headquartered in Helsinki.
Read moreMarket cap
84.64M EUR
Turnover
124.34K EUR
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
26.2.
2026
Annual report '25
All
Research
Webcasts
Press releases
ShowingAll content types
Nanoform Q3 report: Momentum in kernels continues, commercial cGMP manufacturing license received, first near-term target for 2026 set
Inside information made public: Nanoform Granted European Commercial cGMP Manufacturing License
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio